'This is the future of cancer treatment, we believe.' Eli Lilly CEO David Ricks said that Loxo Oncology has 'harnessed the power of emerging science' and that Lilly's acquisition of Loxo can help treat cancer globally.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly to Buy Loxo Oncology in Deal It Values at About $8 BillionEli Lilly said it is buying Loxo Oncology for $235 a share—a 68% premium from Friday’s closing price—in cash, a deal that expands the biopharmaceutical company’s oncology-treatment portfolio.
Lire la suite »
Eli Lilly to buy Loxo Oncology in $8 billion cancer pushThe pharmaceutical company says it is buying Loxo Oncology for $235 a share in cash, a deal that expands the company’s cancer-treatment portfolio.
Lire la suite »
Eli Lilly to spend about $8B on Loxo OncologyEli Lilly is spending about $8 billion in cash to buy Loxo Oncology, as the drugmaker bulks up on cancer treatments that target certain gene abnormalities. Loxo Oncology could launch a drug next year and targets an abnormality that occurs in several tumor types, including some lung and...
Lire la suite »
Pharma giant Eli Lilly just made an $8 billion bet on a cutting-edge scientific approach that uses DNA to treat cancerEli Lilly's $8 billion acquisition of biotech Loxo Oncology is a notably large deal for Eli Lilly, but it could be done again, its CEO said.
Lire la suite »
Lilly to buy Loxo Oncology in $8 billion cancer pushEli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 bill...
Lire la suite »
Eli Lilly’s $8 bln cancer deal is a worthy wagerThe drug giant reckons it’ll take years to get a good return on its pricey acquisition of Loxo. But the upstart has had startling success figuring out why rare cancerous mutations occur, rather than where. Longer term, that should make for plenty of targets – and sticky prices.
Lire la suite »
Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment
Lire la suite »
Stocks making the biggest moves premarket: Tesla, CVS Health, Eli Lilly, Netflix & moreSome of the names on the move ahead of the open.
Lire la suite »